Currently, the research focused on the diagnosis of MCI indicates that the biomarkers in the cerebrospinal fluid (tau protein and Aβ protein) are the most valuable predictors that can evaluate the time when elderly people or MCI patients progress into AD patients. Here, MAPT is linked to Alzheimer disease.